Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint
October 22, 2021
Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
October 11, 2021
Ocular Therapeutix™ Announces Appointment of Karen-Leigh Edwards as Senior Vice President of Technical Operations
September 28, 2021
Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors
September 22, 2021
Ocular Therapeutix™ Updates Monthly In-Market Unit Sales of DEXTENZA® Billable Inserts
September 13, 2021
Ocular Therapeutix™ to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021
Ocular Therapeutix™ to Present at the H.C. Wainwright Ophthalmology Virtual Conference
August 10, 2021
Ocular Therapeutix™ Reports Second Quarter 2021 Financial Results and Business Update
August 09, 2021
Ocular Therapeutix™ Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases
August 05, 2021
Ocular Therapeutix™ Announces First Patient Dosed in U.S.-based Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet Age-Related Macular Degeneration
July 29, 2021
Ocular Therapeutix™ To Report Second Quarter 2021 Financial Results
July 28, 2021
Ocular Therapeutix™ To Present Clinical Data at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
July 23, 2021
Ocular Therapeutix™ Announces Second Quarter 2021 Preliminary Net Product Revenue of $11.7 Million
July 22, 2021
Ocular Therapeutix™ and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dry Age-Related Macular Degeneration
June 29, 2021
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
May 26, 2021
Ocular Therapeutix™ Reports First Quarter 2021 Financial Results and Business Update
May 05, 2021
CORRECTING and REPLACING Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 03, 2021
Ocular Therapeutix™ Fulfills Post-Marketing Approval Requirements for ReSure® Sealant
May 03, 2021
Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 29, 2021
Ocular Therapeutix™ To Report First Quarter 2021 Financial Results
April 28, 2021
Ocular Therapeutix™ Reports Fourth Quarter and Year End 2020 Financial Results and Business Update
March 11, 2021
Ocular Therapeutix™ Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
March 04, 2021
Ocular Therapeutix™ Announces First Patient Dosed in Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease
March 01, 2021
Ocular Therapeutix™ To Report Fourth Quarter and Year End 2020 Financial Results
February 25, 2021
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
February 24, 2021
Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2021 – Virtual Edition
February 12, 2021
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 04, 2021
Ocular Therapeutix™ Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients with Primary Open Angle Glaucoma or Ocular Hypertension at the 10th Annual Glaucoma 360 New Horizons Forum
January 20, 2021
Ocular Therapeutix™ Promotes Michael Goldstein, MD, MBA, to President, Ophthalmology and Appoints Rabia Gurses Ozden, MD as Senior Vice President, Clinical Development
January 07, 2021
